Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology (original) (raw)
Fig 4
FACS Analysis of Tumor and Spleen T Cell Populations from CT26 Tumor-Bearing Mice.
CT26 colon tumor cells (1x106) were implanted subcutaneously into female BALB/c mice. At day 7 post implantation, tumor-bearing mice were randomized and dosed with 10 mg/kg of antibody IP Q3D×3. On day 15 post implantation, tumors were harvested, dissociated into single-cell suspensions, and stained for flow cytometry (n = 8/group); data are representative of two independent experiments. Cytokine production data are representative of one experiment utilizing ex vivo ICS and one experiment utilizing ICS following peptide re-stimulation. A-B. Percentages of polyclonal CD8+ T cells of CD45+ cells (left), CD4+ T cells of CD45+ cells, or FoxP3+ cells of CD4+ T cells (right) in tumors (A) and spleens (B) after the indicated treatments. C. Representative frequencies and plots and of AH1-specific (tetramer+) CD8+ T cells as a percentage of total TIL. D. Representative frequencies and plots of IFN-γ/TNF-α+ cells of total tumor-infiltrating CD8+ T cells following in vitro AH1 peptide stimulation. E. Representative frequencies and plots of AH1-specific (tetramer+) CD8+ T cells as a percentage of total splenic CD8+ T cells. F. Representative frequencies and plots of IFN-γ/TNF-α+ cells of total splenic CD8+ T cells following in vitro AH1 peptide stimulation. Error bars depict the SEM.